PMID- 26157761
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150709
LR  - 20220321
IS  - 2287-8882 (Print)
IS  - 2287-903X (Electronic)
IS  - 2287-8882 (Linking)
VI  - 3
IP  - 1
DP  - 2015 Mar
TI  - Predictors of survival in prostate cancer patients with bone metastasis and 
      extremely high prostate-specific antigen levels.
PG  - 10-5
LID - 10.1016/j.prnil.2015.02.006 [doi]
AB  - PURPOSE: Prostate-specific antigen (PSA) is a surrogate marker of disease 
      progression; however, its predictive ability in the extreme ranges is unknown. We 
      determined the predictors of survival in patients with bone metastatic prostate 
      cancer (BMPCa) and with extremely high PSA levels. METHODS: Treatment-naive 
      patients (n = 248) diagnosed with BMPCa between December 2002 and June 2012 were 
      retrospectively analyzed. Clinicopathological features at diagnosis, namely age, 
      body mass index, serum alkaline phosphatase (ALP) and PSA levels, PSA nadir, time 
      to PSA nadir and its maintenance period, PSA declining velocity, Gleason grade, 
      clinical T stage, pain score, Eastern Cooperative Oncology Group performance 
      score (ECOG PS), and the number of bone metastases were assessed. The patients 
      were stratified according to PSA ranges of <20 ng/mL, 20-100 ng/mL, 
      100-1000 ng/mL, and 1000-10,000 ng/mL. Study endpoints were castration-resistant 
      PCa (CRPC)-free survival and cancer-specific survival (CSS). RESULTS: Patients 
      with higher PSA and ALP levels showed more bone lesions (P < 0.001). During the 
      follow-up period (median, 39.9 months; interquartile range, 21.5-65.9 months), 
      there were no differences between the groups in terms of the survival endpoints. 
      High ALP levels, shorter time to PSA nadir, and pain were associated with an 
      increased risk of progression to CRPC, and high ALP levels, ECOG PS >/= 1, and 
      higher PSA nadir independently predicted CSS. CONCLUSIONS: PSA response to 
      androgen deprivation therapy and serum ALP are reliable predictors of survival in 
      patients with BMPCa presenting with extremely high PSA levels. These patients 
      should not be deterred from active treatment based on baseline PSA values.
FAU - Koo, Kyo Chul
AU  - Koo KC
AD  - Departments of Urology and Urological Science Institute, Yonsei University 
      College of Medicine, Seoul, South Korea.
FAU - Park, Sang Un
AU  - Park SU
AD  - Departments of Urology and Urological Science Institute, Yonsei University 
      College of Medicine, Seoul, South Korea.
FAU - Kim, Ki Hong
AU  - Kim KH
AD  - Departments of Urology and Urological Science Institute, Yonsei University 
      College of Medicine, Seoul, South Korea.
FAU - Rha, Koon Ho
AU  - Rha KH
AD  - Departments of Urology and Urological Science Institute, Yonsei University 
      College of Medicine, Seoul, South Korea.
FAU - Hong, Sung Joon
AU  - Hong SJ
AD  - Departments of Urology and Urological Science Institute, Yonsei University 
      College of Medicine, Seoul, South Korea.
FAU - Yang, Seung Choul
AU  - Yang SC
AD  - Departments of Urology and Urological Science Institute, Yonsei University 
      College of Medicine, Seoul, South Korea.
FAU - Chung, Byung Ha
AU  - Chung BH
AD  - Departments of Urology and Urological Science Institute, Yonsei University 
      College of Medicine, Seoul, South Korea.
LA  - eng
PT  - Journal Article
DEP - 20150212
PL  - Korea (South)
TA  - Prostate Int
JT  - Prostate international
JID - 101605566
PMC - PMC4494633
OTO - NOTNLM
OT  - Alkaline phosphatase
OT  - Bone
OT  - Metastasis
OT  - Prostate cancer
OT  - Prostate-specific antigen
OT  - Survival
EDAT- 2015/07/15 06:00
MHDA- 2015/07/15 06:01
PMCR- 2015/02/12
CRDT- 2015/07/10 06:00
PHST- 2014/11/26 00:00 [received]
PHST- 2014/12/26 00:00 [accepted]
PHST- 2015/07/10 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/07/15 06:01 [medline]
PHST- 2015/02/12 00:00 [pmc-release]
AID - S2287-8882(15)00007-0 [pii]
AID - 10.1016/j.prnil.2015.02.006 [doi]
PST - ppublish
SO  - Prostate Int. 2015 Mar;3(1):10-5. doi: 10.1016/j.prnil.2015.02.006. Epub 2015 Feb 
      12.